LifeSpan BioSciences Enters into Agreement with Major Pharmaceutical Company for Expanded DrugTarget Localization Database
lifespan BioSciences, Inc. announced an agreement, valued at $2 million, with an undisclosed major international pharmaceutical company for a subscription to LifeSpan's DrugTarget Database(TM). This subscription agreement marks the 50th subscriber to LifeSpan's DrugTarget data.
LifeSpan's DrugTarget Database is the industry's largest resource for proprietary human protein localization data for drug targets in eight important gene families, including G protein-coupled receptors (GPCRs), nuclear hormone receptors (NHRs), kinases, ion channels, phosphatases, proteases, phosphodiesterases, and transporters. The database provides subscribers with information on protein expression in 75 human tissues and diseases at the cellular level. It is used by pharmaceutical companies to identify and validate new target genes for drug discovery efforts.
Under the terms of the agreement, the subscriber will nominate 50 additional genes for study and inclusion in the expanded database over a two-year period. Access to the database and updates will be provided in real time throughout the development period. The database already includes 822 comprehensive immunohistochemistry reports with localization information on more than 400 potential drug target genes selected by pharmaceutical company subscribers, including 337 GPCRs, 45 NHRs, and a subset of proteases and kinases. The expanded database will include ion channels, secreted proteins, phosphatases, and other families of genes.
"The genomics and proteomics revolution has left scientists with too many early-stage targets for the next generation of drug discovery efforts. Our molecular pathology approach provides the pharmaceutical industry with information that allows prioritization of potential targets and selection of those with the most significance to major human diseases," said Dr. Glenna C. Burmer, LifeSpan's Chief Scientific Officer.
LifeSpan is using specific antibodies together with its extensive bank of human tissue specimens to measure expression of drug target candidates in a wide range of normal and diseased tissues. The results are interpreted by LifeSpan's in-house pathologists and used to construct a relational database, which also contains detailed information on protein expression in each cell type of the tissues and diseases studied, accompanied by digital images.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
